Company: MYGN
Filing Date: 2025-02-28
Form Type: 10-K
Source: 0000899923-25-000019
Chunk: 175

Company: MYRIAD GENETICS INC
Filing Date: 2025-02-28
Form: 10-K
Item: Item 8
Chunk 175
---
 income in the Consolidated Statements of Operations. 

17.    DIVESTITURE

On August 1, 2024, the Company completed the sale of its EndoPredict business to Eurobio Scientific ("Eurobio") for net cash consideration of $10.0 million, subject to customary closing adjustments. The transaction was accounted for as a sale of business. The Company recognized a total net loss, including transaction expenses, of $12.4 million during the twelve months ended December 31, 2024 in connection with this sale. The loss is included in Goodwill and long-lived asset impairment charges on the Consolidated Statements of Operations. The recognized loss included the release of $4.4 million of foreign currency translation adjustments previously included in Accumulated other comprehensive income (loss). As part of the transaction, the Company licensed the rights from Eurobio to continue to sell EndoPredict as a laboratory developed test outside of the European Union and licensed to Eurobio the right to sell Prolaris in vitro diagnostic kits outside the U.S.

18.    SUPPLEMENTAL CASH FLOW INFORMATION

The Company's supplemental cash flow information for the respective periods are as follows:December 31,(in millions)202420232022Cash paid for income taxes$2.7 $1.9 $1.8 Cash paid for interest1.9 1.4 — Non-cash investing and financing activities:Change in operating lease right-of-use assets and lease liabilitiesOperating lease right-of-use assets$3.1 $(31.0)$46.9 Operating lease liabilities(3.1)36.7 (46.9)Tenant improvement allowance not yet received— — 22.9 Purchases of property, plant and equipment and capitalization of internal-use software in accounts payable and accrued liabilities6.4 6.9 10.0 

103

Table of Contents

Item 9.    CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE

Not applicable.

Item 9A.    CONTROLS AND PROCEDURES

1.    Disclosure Controls and Procedures

We maintain disclosure controls and procedures (Disclosure Controls) within the meaning of Rules 13a-15(e) and 15d-15(e) under  the Exchange Act. Our Disclosure Controls are designed to ensure that information required to be disclosed by us in the reports we file or submit under the Exchange